Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
OwnerChil-Yong Kang, Gyoung Nyoun Kiminventors
Life of this patent
Estimating the term…
Abstract
Immunization platforms, immunization regimes and medicaments useful for inducing an immune response in a mammal and preventing or treating a pathogenic infection in a mammal, wherein said immunization platforms and medicaments comprise a recombinant vesicular stomatitis virus (VSV) of one serotype and a rVSV of another serotype and are used in a prime-boost immunization regime. In aspects of the invention one VSV serotype is Indiana and the other VSV serotype is New Jersey.
Claims12
A method for preventing or treating an infection caused by a pathogen, said method comprising:
- a) administering to a subject a dose of an effective amount of a first immunogenic composition comprising a full length recombinant vesicular stomatitis virus (rVSV) Indiana serotype (rVSVInd) expressing one or more proteins of the pathogen, and
- b) administering to the subject a dose of an effective amount of a second immunogenic composition comprising a full length rVSV New Jersey serotype (rVSVNJ) expressing the one or more proteins of the pathogen;
- wherein the immunogenic composition comprising the rVSVInd is administered as a prime immunogen and the vaccine comprising the rVSVNJ is administered as a booster immunogen at about 3 weeks, or later, after administration of the prime immunogen;
- wherein the rVSVInd comprises an Indiana serotype mutant M protein comprising a methionine at position 51 changed to an arginine (M51R substitution), and the rVSVNJ comprises a New Jersey serotype mutant M protein comprising a methionine at position 48 changed to an arginine and a methionine at position 51 changed to an arginine (M48R-M51R substitution);
- and
- wherein the one or more proteins of the pathogen comprises a B-cell and/or a T-cell epitope.
A method for inducing an immune response in a subject to a pathogen wherein the method comprises the following steps:
- a) administering to a subject a dose of an effective amount of a first immunogenic composition comprising a full length recombinant vesicular stomatitis virus (rVSV) Indiana serotype (rVSVInd) expressing one or more proteins of the pathogen, and
- b) administering to the subject a dose of an effective amount of a second immunogenic composition comprising a full length rVSV New Jersey serotype (rVSVNJ) expressing the one or more proteins of the pathogen;
- wherein the immunogenic composition comprising the rVSVInd is administered as a prime immunogen and the immunogenic composition comprising the rVSVNJ is administered as a booster immunogen at about 3 weeks after administration of the prime immunogen;
- wherein the rVSVInd comprises an Indiana serotype mutant M protein comprising a methionine at position 51 changed to an arginine (M51R substitution);
- and the rVSVNJ comprises a New Jersey serotype mutant M protein comprising a methionine at position 48 changed to an arginine and a methionine at position 51 changed to an arginine (M48R-M51R substitution);
- and
- wherein the one or more proteins of the pathogen comprises a B-cell and/or a T-cell epitope.
A method for preventing or treating an infection caused by a pathogen or for inducing an immune response in a subject to the pathogen, said method comprising:
- a) administering to a subject a dose of an effective amount of a first immunogenic composition comprising a full length recombinant vesicular stomatitis virus (rVSV) New Jersey serotype (rVSVNJ) expressing one or more proteins of the pathogen, and
- b) administering to the subject a dose of an effective amount of another immunogenic composition comprising a full length rVSV Indiana serotype (rVSVInd) expressing the one or more proteins of the pathogen;
- wherein the immunogenic composition comprising the rVSVNJ is administered as a prime immunogen and the immunogenic composition comprising the rVSVInd is administered as a booster immunogen at about 3 weeks after administration of the prime immunogen;
- wherein the rVSVNJ comprises a New Jersey serotype mutant M protein comprising a methionine at position 48 changed to an arginine and a methionine at position 51 changed to an arginine (M48R-M51R substitution), and the rVSVInd comprises an Indiana serotype mutant M protein comprising a methionine at position 51 changed to an arginine (M51R substitution);
- and
- wherein the one or more proteins of the pathogen comprises a B-cell and/or a T-cell epitope.
Dependencies are inferred from the claim text.